Hepatitis C virus (HCV), a member of Flaviviridae family (genus Hepacivirus) is mostly responsible for chronic hepatitis and hepatocellular carcinoma (
1,
2). Over 170 million individuals are infected with HCV around the world (
3). The reported rate of HCV in Syria, Saudi Arabia and Jordan is 1%, 2.5% and 1.7%, respectively (
4-
6). HCV has a positive sense RNA and is about 50 nm in diameter (
1,
7). Targeted site of HCV is hepatocytes of the liver that may start replication there. It is reported that about fifty virions are produced by each infected cell per day. Hepatitis C virus may also replicate in peripheral blood mononuclear cells, which may lead to high level of immunological disorders in chronically infected HCV patients. Due to RNA virus and lack of proof reading ability, mutation rate is very high in HCV genome. This high mutation rate is responsible for the existence of different genotypes (
8). Six primary genotypes and several subtypes are known globally (
9). Genotypes 1, 2 and 3 are circulated worldwide while the majority of subtypes 1a and 1b have been reported in Europe and the United States of America (
9-
13). In North America, Japan, and Europe the most frequently found subtypes are 2a and 2b while 2c is very common in Italy (
10-
13). HCV genotype 4 is mostly reported in Middle East and North Africa (
14,
15), while genotypes 5 and 6 are only distributed in Hong Kong and South Africa (
16,
17). Transmission of HCV from the infected to healthy individuals may occur by different ways such as contaminated syringes, sharing contaminated tooth brushes, razors etc. It may also be transmitted by sexual contact with infected persons (
18). Hepatitis C virus was also found in saliva and breast milk, but a transmission through breast milk has not been reported (
19). Transmission via needle stick injury is documented, about 5% (
20). Different diagnostic methods are used to detect HCV including ELISA, recombinant immunoblot assay, and polymerase chain reaction (PCR). PCR is considered to be the most accurate and reliable method that can detect the virus after one to two weeks of infection while by antibodies it may take a long time (
21-
23). No vaccines are available for protection against HCV (
24). About 50% to 80% of the infected patients get chronic infection and 40% to 80% of these patients may clear their body from infection via treatment (
25-
27). Patients with chronic HCV infection should be vaccinated against Hepatitis A virus (HAV) and Hepatitis B virus (HBV) infections and should avoid the use of alcohol and liver toxic agents (
22). Different antiviral drugs are used to treat HCV (
28). Depending on HCV genotypes, 24 or 28 week treatments including interferon alpha (pegylated in some cases) and ribavirin are currently in practice (
22). Various other therapies are claimed to be helpful in HCV treatment such as milk thistle, and colloidal silver and ginseng, but no valid scientific evidence for the efficacy of these agents on the virus has been reported (
29). Hepatitis C virus prevalence range in different geographical regions of Khyber Pukhtunkhwa (KPK) has been reported from 4.1 to 36% in (
30,
31).